Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Drug shows promise for stopping excessive sweating

NCT ID NCT01855256

Symptom relief Sponsor: University Hospital, Brest Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tested the drug oxybutynin in 62 adults with excessive sweating (hyperhidrosis). Participants took either oxybutynin or a placebo, starting at a low dose and increasing gradually. The study measured how well the drug reduced sweating and improved quality of life, while also tracking side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Oxybutynin
What this could lead to
If it works, this could provide a non-surgical treatment option for people with excessive sweating.
What could go wrong
This is a small, completed Phase 3 trial. While results are promising, the drug may cause side effects and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

62 people

The number who actually took part.

Start date

Jun 2013

Finished

Mar 2014

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age greater than 18 years * Patient affiliated to social security or beneficiary of such a regime * Patient able to consent * Patient with hyperhidrosis, generalized or localized (palmar, plantar, axillary) and whose score HDSS (Hyperidrosis Disease Severity Scale) is greater than two. Exclusion Criteria: * Age less than 18 years * Patient who can't be followed * Patient participating in another clinical trial * Pregnant * Woman breastfeeding * Hypersensitivity to oxybutynin or any of the excipients * Risk of urinary retention related disorders uretroprostatiques * Intestinal obstruction * Toxic megacolon * Intestinal atony * Severe Ulcerative Colitis * Myasthenia * Closure glaucoma the anterior chamber angle or slightly deep

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hyperhidrosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hyperhidrosis hyperhidrosis palmaris ET plantaris

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hyperhidrosis

Contacts and locations

Locations

  • CHG Landerneau

    Landerneau, 29800, France

  • CHG de Morlaix

    Morlaix, France, 29600, France

  • Dermatologist'S Office

    Quimper, 29000, France

  • Hospital, Brest

    Brest, 29609, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.